Bladder cancer is one of the most frequent malignancies worldwide [1] . For decades, it has been known that bladder cancer is heterogenous and therefore new markers are still needed for many different questions concerning diagnosis and therapy. Tumor grade and stage alone are not accurate in predicting the biological behavior and thus guiding the choice of treatment, especially in high risk cases [2] [3] [4] .
assay that can diagnose bladder cancer confined by the urothelium/CIS could fulfil the criterion to differ between both. This model has also been confirmed by other publications in the past [16] [17] [18] .
There is a clinical need for markers to determinate the recurrence and progression of bladder cancer; these markers will contribute to establishing better treatments for the individual patient. Molecular staging of urological tumors will allow for the selection of cases that will require systemic and/or target treatment [19, 20] .
Clinical needs in uro-oncology are related to diagnosis, prognosis, and treatment. Uro-oncology is diverse, since genitourinary tumors differ histologically in their origin and various clinical behavior [21] .
In the past, more and more genetic and epigenetic markers could show its predictive and/or prognostic value regarding overall survival and even cancer specific survival. As an example of how a tumor marker can predict therapeutic success, the results of the phase 2 KEYNOTE-052 (NCT02335424) study showed how a marker could influence therapeutic decisions on one hand, and that negative marker results were also not a certain predictor of therapeutic success [22] . PD-L1 positive is defined as a combined positive score (CPS) ≥10. In patients with CPS <10 (n = 251), the overall response rate (ORR) was 20%, while in patients with CPS ≥10 (n = 110), the ORR was 47%. This shows that even patients with negative CPS could have the benefit of pembrolizumab in this case.
This Special Issue has been introduced with the aim of offering the possibility of publishing new research results in the field of bladder cancer basic research. While editing this Special Issue, we have learned that enormous enthusiasm is necessary move forward in bladder cancer research. In our eyes, bladder cancer is, on one hand, a very heterogenous malignancy, which is why it so difficult to focus on a single bladder cancer marker in diagnostic and follow-up. Due to the mass of all these markers, it is impossible to report them all. This Special Issue tries to highlight the role of bladder cancer markers in diagnosis and the most important biomarkers studied and recently reported. Due to the determination of recurrence and progression, markers will contribute to establishing better treatments for the individual patient. Molecular staging of urological tumors will allow for cases to be selected that will require systemic treatment. However, as above-mentioned at the moment, it is not clear if clinical decisions based on tumor markers are still a dream, or perhaps a real nightmare. However, is still necessary and more important than before to integrate the same objectives under basic and clinical research.
The editors thank all submitting authors for their efforts and time spent for each manuscript. The lead editor would like to thank all editors for the time spent in reviewing, assigning reviews, and commenting on the submitted manuscripts. As an editorial team, we hope that this Special Issue will prove useful in research work regarding bladder cancer in the future. Hopefully, many researchers will use any kind of art to improve their professional success to ameliorate diagnostics and therapy in bladder cancer!
